Investing.com - Can Fite Biopharma ADR reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Can Fite Biopharma ADR announced earnings per share of $0.00 on revenue of $205K. Analysts polled by Investing.com anticipated EPS of $-0.16 on revenue of $100K.
Can Fite Biopharma ADR shares are down 1.24% from the beginning of the year and are trading at $0.840 , down-from-52-week-high.They are outperforming the S&P/TSX which is down 3.25% from the start of the year.
Can Fite Biopharma ADR shares lost 0.02% in intra-day trade the report.
Can Fite Biopharma ADR follows other major Healthcare sector earnings this month
Can Fite Biopharma ADR's report follows an earnings beat by Pfizer on May 3, who reported EPS of $1.62 on revenue of $25.66B, compared to forecasts EPS of $1.49 on revenue of $24.1B.
Eli Lilly had beat expectations on April 28 with first quarter EPS of $2.62 on revenue of $7.81B, compared to forecast for EPS of $2.29 on revenue of $7.29B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar